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Abstract 
Background: Tuberculin skin test based on in vivo intradermal inoculation of purified protein derivative from Myco-
bacterium bovis (bPPD) is the diagnostic test for the control and surveillance of bovine tuberculosis (bTB).
Methods: Proteomic analysis was performed on different bPPD preparations from M. bovis, strain AN5. Proteins 
were precipitated from bPPD solutions by TCA precipitation. The proteome of bPPD preparations was investigated 
by bottom-up proteomics, which consisted in protein digestion and nano-LC–MS/MS analysis. Mass spectrometry 
analysis was performed on a Q-exactive hybrid quadrupole-Orbitrap mass spectrometer coupled online to an Easy 
nano-LC1000 system.
Results: Three hundred and fifty-six proteins were identified and quantified by at least 2 peptides (99% confidence 
per peptide). One hundred and ninety-eight proteins, which had not been previously described, were detected; 
furthermore, the proteomic profile shared 80 proteins with previous proteomes from bPPDs from the United King-
dom and Brazil and 139 protein components from bPPD from Korea. Locus name of M. bovis (Mb) with orthologs from 
M. tuberculosis H37Rv, comparative gene and protein length, molecular mass, functional categories, gene name and 
function of each protein were reported. Ninety-two T cell mycobacterial antigens responsible for delayed-type hyper-
sensitivity were detected, fifty-two of which were not previously reported in any bPPD proteome. Data are available 
via ProteomeXchange with identifier PXD005920.
Conclusions: This study represents the highest proteome coverage of bPPD preparations to date. Since proteins 
perform cellular functions essential to health and/or disease, obtaining knowledge of their presence and variance 
is of great importance in understanding disease states and for advancing translational studies. Therefore, to better 
understand Mycobacterium tuberculosis complex biology during infection, survival, and persistence, the reproduc-
ible evaluation of the proteins that catalyze and control these processes is critically important. More active and more 
specific tuberculins would be desirable. Indeed, many antigens contained within bPPD are currently responsible for 
the cross-reactivity resulting in false-positive results as they are shared between non-tuberculous and tuberculous 
mycobacteria.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Tuberculosis (TB), a zoonotic disease, is a major global 
human health problem, with 10.4 million new cases of 
active disease and nearly 1.8 million deaths estimated 
for 2015 [1]. The disease has similarly heavy conse-
quences for a broad range of animal species thus being 
a recognized public veterinary health problem in many 
countries [2, 3].
Tuberculosis in bovines (bTB), caused predominantly 
by Mycobacterium bovis (M. bovis) a member of the 
Mycobacterium tuberculosis complex, is a disease still 
endemic in many countries [4]. bTB is the cause of sig-
nificant economic hardship to the livestock industry with 
estimates of >50 million cattle infected worldwide [5] 
and is of zoonotic importance [6]. Indeed, although M. 
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responsible for bTB, however, it may cause tuberculo-
sis in humans (hTB) both in developing and developed 
countries [7–9].
Moreover, bTB is subject to comprehensive control 
measures in order to limit both zoonotic transmission 
and economic losses. Such control is typically based on 
test-and-slaughter schemes, which require the accurate 
diagnosis of infected animals [10].
The diagnostic test for the control and surveillance of 
bTB used worldwide is the Tuberculin Skin Test (TST), 
which is based on in  vivo intradermal inoculation of 
purified protein derivative from M. bovis (bPPD) alone 
or in combination with M. avium (aPPD). Those ani-
mals that react to PPD are isolated and slaughtered [11, 
12]. Despite intensive eradication efforts over decades, 
bTB persists as a costly disease with adverse impacts on 
animal health and welfare, trade of animals and animal 
products, and livelihoods of producers, and continues to 
be a problem with global perspectives [4, 13]. It has been 
suggested that TST is a good herd test but a poor test 
for identifying individual infected animals [4]. Further-
more limitations in specificity and sensitivity of bPPD are 
additional factors contributing to the persistence of bTB 
[14]. However, TST is the gold standard for determining 
whether an individual animal is infected with bTB.
bPPD is a poorly characterized and ill-defined mix of 
proteins, lipids, and carbohydrates [11, 13] and little is 
known regarding what compounds are responsible for 
the delayed-type hypersensitivity (DTH) response [15, 
16]. More defined knowledge on PPD composition and 
contribution of individual antigens in TST would give a 
better insight into the molecular mechanism behind the 
complex would therefore allow a better selection of pro-
teins specific to M. tuberculosis [17]. Therefore, the iden-
tification of the molecular composition would facilitate 
the development of a more refined reagent [15].
A few proteomic studies have been performed on 
bPPD composition. Borsuk et  al. [18] reported the first 
proteomic study from bPPD from the United Kingdom 
(UK) and from Brazil (BR). Cho et al. [19] described pro-
teome profiles of bPPD from Korea (KR). More recently, 
Gcebe et al. [20] carried out a proteomic analysis of bPPD 
obtained from Prionics at The Netherlands.
The aim of the present paper is to report proteomic 
profiles detected on four bPPD preparations used for 




Four bPPD preparations from M. bovis, strain AN5, 
were examined. They were from Spain (S), manufac-
tured by CZV company [CZ Veterinaria S.A., Porriño, 
(Pontevedra) Spain] and commercialized in Spain, Por-
tugal, France, Germany, Ireland, Greece, United King-
dom, Belgium, Hungary, Bulgaria, Italy, Romania; two 
from Italy (one prepared by Istituto Zooprofilattico 
dell’Umbria e delle Marche, Perugia  (Ip) and one by Isti-
tuto Zooprofilattico Sperimentale dell’Abruzzo e del 
Molise “G. Caporale”, Teramo  (It), respectively) and com-
mercialized in Italy and one from Netherlands (NL), 
manufactured by Prionics Lelystad BV, Lelystad, Holland 
and commercialized in Germany, Denmark, Sweden, 
Norway and Netherlands.
Chemicals
All chemicals were from Sigma (St. Louis, MO), unless 
otherwise specified.
Protein digestion and peptide dimethylation labelling
Proteins were precipitated from bPPD solutions by TCA 
precipitation. Briefly, proteins were precipitated in 10% 
TCA overnight, then pelleted at 12,000 g for 30 min at 4 
°C. Pellets were washed with (1) ethyl ether (2) acetone. 
Proteins were resuspended in 100  mM triethyl ammo-
nium bicarbonate buffer (TEAB) containing 0.2% SDS. 
Protein content was determined by the BCA protein 
assay using BSA as standard for the calibration curve 
(BCA protein assay, Thermo Scientific, Rockford, USA). 
For each sample, a 100 μg aliquot was subjected to pro-
tein reduction (10  mM DTT, 1  h at 37  °C) and alkyla-
tion (24 mM iodoacetamide, 1 h at 37 °C). The excess of 
iodoacetamide was quenched by additional 2 mM DTT. 
SDS concentration was brought to 0.05% by addition of 
HPLC water; then, 1 μg of proteomics grade trypsin was 
added, and digestion was allowed to proceed overnight at 
37 °C.
Samples were labelled by either “light” (L), “medium” 
(M) or “heavy” (H) dimethyl labelling [21]. An aliquot 
of each sample, containing 25  μg of protein, was trans-
ferred to a separate Eppendorf vial. Then, 4 μL of either 
4% (v/v) regular formaldehyde (L) or  CD2O (M), or 
13CD2O (H) plus 4 μL of either 0.6 M  NaBH3CN (L, M) 
or  NaBD3CN (H) were added. Reductive amination 
was allowed to proceed at room temperature for 1  h 
with shaking. To quench the reaction, 16 μL of 1% (v/v) 
ammonia solution and 8 μL of 5% formic acid were added 
to the samples. Samples were labelled in duplicates with 
label swapping, as follows: sample S (L, M, H), sample 
 It (M, L), sample NL (H, L), sample  Ip (H, M). Triplets 
were obtained by combining 5  μg of each labelled sam-
ple as follows: (1) S(L):It(M):NL(H); (2)  It(L):S(M):Ip(H); 
(3) NL(L):Ip(M):S(H). Sample S was used as reference 
sample: thus, it was present in all triplets. Each mix was 
fractionated by SCX StageTips [22] using Empore SCX 
Extraction Disks. Briefly, samples were diluted 20-fold in 
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solution A (0.5% formic acid, FA in 80% ACN), and then 
loaded onto a column prepared from a 10  μL micropi-
pette tip stacked with two layers of the SCX resin, pre-
viously conditioned with 20  µl of solution A. The plugs 
were washed twice with 20 μL of solution A. Then, pep-
tides were stepwise eluted by delivering six 14 μL aliquots 
of eluent of increasing ionic strength. The first five elu-
ent solutions contained 20% acetonitrile and 0.5% for-
mic acid (v/v) plus the following amount of ammonium 
acetate: (1) 50 mM, (2) 75 mM, (3) 100 mM, (4) 150 mM, 
(5) 250 mM. The sixth eluent solution was composed of 
20% acetonitrile and 500 mM ammonium acetate. Eluates 
were evaporated to dryness and resuspended in 12 μL of 
mobile phase A (see below).
Nano‑LC–MS/MS and data analysis
Mass spectrometry analysis was performed on a 
Q-Exactive Hybrid Quadrupole-Orbitrap Mass Spec-
trometer coupled online to an Easy nano-LC1000 system 
(Thermo Fisher Scientific, Germany). Peptide mixtures 
(3  µL) were loaded at a flow rate of 500  nL/min onto a 
silica capillary tip (75  µm i.d., length 10  cm) packed in 
house with 3  µm  C18 silica particles (Dr. Maisch, Ger-
many). Gradient elution was from 8% B (0,1% FA in 80% 
ACN) to 35% in 55 min, then from 35% B to 100% B in 
5 min. Column equilibration (20 min) was at 2% B. MS 
acquisition was performed in positive ion mode with a 
nanoelectrospray voltage of 1800  V. Mass spectra were 
obtained in data-dependent acquisition (DDA) mode, 
using a top 12 method consisting in a survey full scan 
across the m/z range 350–1800, followed by MS/MS 
scans on the twelve most intense precursor ions accu-
mulated for a maximum of 60  ms. Full scan acquisition 
parameters were: 70,000 FWHM, AGC target 1e6, maxi-
mum IT 50  ms, scan range 350 to 1800  m/z. Instead, 
dd-MS2 acquisition parameters were set as following: 17 
500 FWHM, AGC target 1e5, maximum IT 60 ms, isola-
tion window 1.6 m/z, scan range 200 to 2000 m/z. Colli-
sion energy was set at 25%.
Raw data were processed by Proteome Discoverer 1.4 
using the Sequest algorithm and searched against the 
protein sequence database of Mycobacterium tubercu-
losis Complex (June 2015, 6415 proteins). Search crite-
ria were set as follows: enzyme trypsin, maximum two 
missed cleavages, Dimethyl (Any N-Terminus), Dimethyl 
(K), Carbamidomethyl (C) as static modifications (dime-
thyl modifications were set to either “light”, “medium” or 
“heavy” in three parallel searches), Oxidation (Met) as 
dynamic modification, MS tolerance 10  ppm, MS/MS 
tolerance 0.02 Da. Search results were filtered by q values 
using Percolator [23], integrated in Proteome Discoverer 
(q value <0.01). As negative examples for the classifier, 
Percolator peptide hits derived from searching a decoy 
database composed of reversed protein sequences were 
used. Protein hits based on two successful peptide iden-
tifications in at least 2 out 3 LC-MS/MS data sets were 
considered valid. Initial quantification was performed 
in Proteome discoverer using default parameters for tri-
plex dimethyl labelling. Advanced quantification, such 
as data normalization and permutation statistical analy-
sis of the peptide ratios was performed using quantita-
tive proteomics p value calculator (QPPC) [24]. Number 
of permutations was set to 10,000. Minimum number of 
observations was 2; thus, proteins identified by two pep-
tides but quantified by a single unique peptide were not 
assigned a fold change. For each binary comparison  (It 
versus S, NL versus S,  Ip versus S) proteins whose fold 
change was either >2.0 or <0.5, with an associated p value 
<0.05 in both replicate analysis were considered differen-
tially abundant. Finally, BoviList and TubercuList data-
bases (http://tuberculist.epfl.ch/) provided information 
on annotated M. bovis and M. tuberculosis H37Rv genes 
and proteins, including molecular weights and func-
tional annotation as well as orthologous genes of these 
two highly related strains. Uniprot (http://www.uniprot.
org/) and KEGG (http://www.kegg.jp/kegg/) databases 
have also been utilized in order to obtain further detailed 
information about proteins of M. bovis, strain AN5 and 
M. tuberculosis, strain H37Rv.
The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the 
PRIDE [25] partner repository with the dataset identifier 
PXD005920.
Results
Identification of bPPD proteins by list‑based nano‑LC‑MS/
MS
The proteome of four bPPD preparations was inves-
tigated by bottom-up proteomics, which consisted in 
protein digestion and nano-LC-MS/MS analysis. Alto-
gether, we identified 356 proteins by 2 or more peptides 
(99% confidence per peptide) in at least 2 out 3 LC-MS/
MS data sets (Fig.  1). A vast majority (~75%) of these 
proteins was found to be shared among four bPPDs. Our 
proteomic profile was composed of 198 not previously 
described proteins; furthermore, nineteen proteins were 
found to be shared with bPPD UK and bPPD BR pro-
teome [18] and seventy-eight with bPPD KR [19]. Sixty 
one proteins were found in common both with bPPD 
UK as well as BR and bPPD KR proteomes (Fig. 2). Addi-
tional file  1: Table S1 reports locus names of M. bovis 
(Mb) and their orthologs from M. tuberculosis H37Rv 
(Rv) including comparative gene and protein lengths, 
molecular mass, functional categories, gene name and 
protein function of both mycobacterium strains. Finally, 
Additional file  1: Table S1 shows a comparative protein 
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expression profile with two previous bPPD proteomic 
analysis [18, 19]. Furthermore, our proteomic profile 
shared 158 proteins with the proteome of M. tuberculo-
sis PPD (MtbPPD) investigated by Prasad et al. [17] who 
were able to identify 265 proteins, the largest number of 
proteins found in MtbPPD so far.
BoviList functional classification codes
The proteins of bPPDs were grouped into eight functional 
categories, with the most representative (33%) being the 
functional category 7 (intermediary metabolism and 
respiration). The other proteins were grouped into the 
functional categories that include  0 (virulence, detoxi-
fication, adaptation—3%), 2 (lipid metabolism—5%), 
3 (information pathways—20%), 4 (cell wall and cell 
processes—13%), 9 (regulatory proteins—4%), 10 (con-
served hypotheticals—19%) and 16 (conserved hypotheti-
cals with an orthologue in M. tuberculosis—2%). From a 
comparative point of view, all proteins we have identified 
in bPPDs have protein equivalents from M. tuberculosis 
H37Rv (http://tuberculist.epfl.ch/), but some of them 
have a different structure and appear to belong to differ-
ent categories (see Additional file  1: Table S1—red and 
blue colors, respectively). Accordingly, protein equiva-
lents from M. tuberculosis H37Rv were grouped in seven 
functional categories.
Mycobacterial proteins containing possible T‑cell antigens
Ninety-two mycobacterial proteins containing pos-
sible T-cell antigens and responsible for delayed-type 
hypersensitivity (DTH) have been identified. M. tuber-
culosis, strain H37Rv, and M. bovis, strain AN5, are 
highly related. Accordingly, some proteins includ-
ing Mb0448, Mb1918c, Mb2002c, Mb3789, Mb3834c, 
Mb3904, Mb3905, just like their orthologs from M. 
tuberculosis H37RV, could have more than 20 different 
T cell epitopes since they are known to be evolutionar-
ily hyperconserved [26, 27]. Numerous proteins such 
as Mb0584, Mb1767, Mb2056c, Mb2057c, Mb2058, 
Mb 2493c, Mb2656, Mb2657, Mb2659c, Mb3155, 
Mb3157c, referred to as latency antigens involved in the 
latent infection, appear to be as a part of the so-called 
dormancy (DosR) regulon, the expression of which is 
observed as part of adaptive response of M. tuberculosis 
complex to hypoxia [28, 29].
Fifty-two T cell antigens including Mb1301c (gene 
name: lprA), Mb1868c (gene name: glcB), Mb1950 (gene 
name: aceA), Mb3646c (gene name: espA), Mb3911c 
(gene name: espB) recently identified from M. tubercu-
losis, strain H37RV, via throughput proteome screening 
[30], have not been reported previously in bPPDs. Four-
teen of them belong to a novel series of in vivo expressed 
M. tuberculosis (IVE-TB) T cell antigens [31, 32]. Two 
reactivation associated antigens, namely Mb0391c (gene 
name: clpB) and Mb2492c (gene name: rplB) and three 
lipoprotein T cell antigens, namely Mb0959 (gene name: 
pstS1), Mb0956c (gene name: pstS2) and Mb0951 (gene 
name: pstS3), known to generate very high levels of 
cytokine secretion [33], were also detected. Nine antigens 
were in common with bPPD KR only [19]. Thirty-one 
antigens were found to be shared both with bPPDs from 
UK as well as BR [18] and with bPPD from KR [19]. Our 
results are summarized in Fig. 3.
Semi‑quantitative analysis of overall protein abundance 
and quantitative comparison of PPDs by dimethyl labelling
Following database searches, qualitative (Additional file 2: 
Table S2) and relative quantitative information (Addi-
tional file 3: Table S3) was obtained. In Additional file 2: 
Table S2, proteins are sorted by the parameter “% total 
weighted spectra”. This is a semi-quantitative measure of 
Fig. 1 Total number of proteins identified within four bPPD prepara-
tions
Fig. 2 Venn diagram showing the unique and shared proteins 
detected in this study compared with previous bPPD proteomic 
profiles
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protein abundance within a mixture (expressed in esti-
mated % weight), which is based on normalized spectral 
counting [34]. It is worthwhile noting that the top ten 
proteins in the list comprise two proteins, namely: ESAT-
6-like protein EsxN and Immunogenic protein MPB63, 
not previously reported. These ten most abundant pro-
teins, whose list is reported in Table 1, constituted over 
67% of total weighted spectra.
Besides estimating average protein abundance by spec-
tral counting, accurate quantification by mass spectrom-
etry based on isotopic labelling was used to compare 
protein levels in each mixture. Proteins whose relative 
abundance changed, in both replicates, significantly 
(p value <0.05) by twofold or more in samples NL,  It,  Ip 
with respect to the reference sample S, are listed in Addi-
tional file 4: Table S4. Comparative analysis by dimethyl 
labelling showed that PPD preparations did not gener-
ally differ significantly in terms of protein composition, 
especially for what concerns the most abundant proteins. 
Two notable exceptions were: (1) protein 14  kDa anti-
gen, whose levels in samples NL and  It were compara-
ble to sample S (fold change close to 1), but was found 
at 0.4-fold change in sample  Ip, and (2) chaperonin 
GroES, whose levels were comparable in samples  Ip and 
 It relative to sample S (fold change close to 1 for  Ip, fold 
change = 0.3 for sample  It, but not found statistically sig-
nificant in both replicates), but was found at relative fold 
change 0.3 in sample NL (Table 1). In total, with respect 
to reference sample S, 44, 34 and 30 proteins were found 
at significantly different levels in samples  It, NL and  Ip, 
respectively. These proteins were mostly present at very 
low levels in all preparations.
Discussion
Comparative proteomics was performed on four bPPD 
preparations. Proteomic profile of all bPPDs was com-
posed of 356 proteins thus representing the highest 
proteome coverage of bPPD preparations to date. We 
deciphered 198 new, never previously reported proteins 
in the protein expression profile. Altogether, 512 proteins 
of M. bovis PPDs, strain AN5, have been identified so 
far. Recently, 132 protein components were also revealed 
from a commercial bPPD preparation [20]. Unfortu-
nately, this last study did not report the complete list of 
proteins identified by Mb number; therefore, it was not 
possible to carry out any comparative studies.
The worldwide used diagnostic test for the control and 
surveillance of bTB is the TST, based on the detection of 
cell mediated immunity under the exposure to bPPD, the 
Fig. 3 Venn diagram showing the unique and shared T cell mycobacterial antigens seen in this study compared to T cell antigens found in other 
bPPD proteomic analysis
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composition of which is highly complex and remains ill-
defined [4, 12].
Since proteins perform cellular functions essential 
to health and/or disease, obtaining knowledge of their 
presence and variance is of great importance in under-
standing disease states and for advancing translational 
studies [35]. Therefore, to better understand M. tubercu-
losis complex biology during infection, survival, and per-
sistence, the reproducible evaluation of the proteins that 
catalyze and control these processes is critically impor-
tant [36].
The emerging field of proteomics has contributed 
greatly to improving our understanding of the M. tuber-
culosis complex quite recently. Proteomics is currently in 
transition from pure basic research to medical applica-
tion [37].
All proteins we detected in bPPDs have human equiva-
lents. All bovine and human proteins were characterized 
by a very strong similarity and a remarkable identity. 
Indeed, all of them shared characteristics such as gene 
and protein length as well as molecular mass and func-
tion. However, we showed that some bovine and human 
proteins encoded by ortholog genes belong to different 
functional categories. Accordingly, it has been shown that 
some genes of members of M. tuberculosis complex can 
have functional polymorphisms and encoded proteins 
responsible for some phenotypic differences between M. 
bovis and the other members of M. tuberculosis complex 
[38].
The proteomic content of the four PPD preparations 
was characterized by a remarkable presence of chaper-
one proteins such as HspX, DnaK, GroEs, GroEl. These 
proteins are known to share a high homology (upwards 
of 70%) and are conserved amongst most mycobacterial 
species [18, 19]. They are believed to be the main proteins 
of the current diagnostic test responsible for high level of 
false positive responses [15].
A quantitative but not qualitative difference in protein 
content was seen in our bPPD proteomes. It is worth-
while noting that subtle differences in culture conditions, 
sterilization methods, protein precipitation methods, 
peptide fractionation process, trypsin efficiency may 
result in differences in proteomic profiles of bPPDs [19].
It has been suggested that proteomic analysis of differ-
ent bPPD preparations could improve current diagnostic 
tests and gain insights into the immune response seen in 
TB disease [19].
We detected 92 mycobacterial proteins potentially 
involved in DTH, thus deciphering 52 new antigens not 
previously reported in bPPDs. Thirty six proteins were 
identified as T cell mycobacterial antigens in bPPDs from 
UK and from BR [18]; bPPD KR proteomes revealed 46 
proteins playing a role in cellular immunity [19]. Alto-
gether, ninety-eight mycobacterial antigens which play a 
central role in DTH have been identified in all examined 
bPPDs. Furthermore, from a comparative point of view, 
a very large number of T cell antigens was found to be 
shared between bPPDs of this study and MtbPPDs [26, 
28–30, 32, 39–41].
The number of novel T cell mycobacterial antigens is 
increasingly detected in bPPD. There is a need to estab-
lish a better and more detailed understanding of T-cell 
biology through comparative investigations to decipher 
immune mechanisms that control mycobacterial infec-
tions which appear to rely heavily on the cellular immune 
system [27, 42]. Accordingly, more active and more spe-
cific tuberculins would be desirable. To date, limited pro-
gress has been achieved in this field, mainly because of 
the ill-defined nature of the antigens present in tubercu-
lins as well as the complexity of PPD production.
We believe that developing more proper and defined 
antigens will be crucial to increase specificity and sensi-
tivity of PPDs. It is worthwhile remembering that there 
is the urgency to improve specificity of PPD since as 
cross-reactive responses to bPPD (false-positive results) 
may occur as many antigens contained within bPPD are 
shared between non-tuberculous and tuberculous myco-
bacterial [4, 11].
Table 1 The most abundant proteins in PPD preparations
Ten most abundant proteins in PPD preparations; last three columns indicate, 
respectively, fold change values for samples  It, NL and  Ip with respect to 
reference S; average fold change is reported in bold italics, whereas values 
relative to each duplicate analysis are reported in italics
a Statistically significant fold change values
Accession Description % Total 
weighted 
spectra
It vs S NL vs S Ip vs S
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Conclusion
Improvement and/or replacement of classical PPD 
composition with novel more specific reagents remain 
demanding [15].
To control TB disease, new strategies are needed to 
prepare better tools based on identification of novel anti-
gens important for developing diagnostic tests which 
could be not only more accurate and sensitive but also 
capable of differentiating infected and uninfected vacci-
nated animals (“DIVA” tests), thus offering perspectives 
to introduce potential vaccination within existing eradi-
cation programs [43, 44].
Indeed, understanding immunity to M. bovis is a con-
tinuing challenge and one that is of interest to the fields 
of human and animal medicine alike [6]. It is important 
to note that ruminant also have greater similarity to 
humans than do the often-used mouse model with regard 
to several aspects of immune physiology, increasing the 
utility of cattle as a model [45]. Therefore, comparative 
immunology studies will continue to provide mutual 
benefit to TB research in both man and animals [46].
Accordingly, the One Health approach, believed to be 
a critical necessity to address zoonotic diseases [2], is 
clearly warranted for tuberculosis. The One Health con-
cept is a worldwide strategy for expanding interdiscipli-
nary collaborations and communications in all aspect 
of health care for humans, animals and the environ-
ment which, as far as tuberculosis disease is concerned, 
can speed the development of new diagnostic tests for 
humans and livestock thus improving tuberculosis sur-
veillance, control, and eradication programs.
Additional files
Additional file 1: Table S1. This table shows: the list of the identified 
proteins within all four bPPD preparations, ordered locus names of M. 
bovis (Mb) and M. tuberculosis, strain H37Rv, (Rv), functional categories of 
identified proteins, their molecular mass, gene and protein lengths and 
gene name and protein function. A comparative protein expression pro-
file with two previous bPPD proteomic analysis is also shown. Differences 
in functional category among identified proteins are in blue; differences 
in molecular mass, gene and protein lengths are in red. These findings 
were from TubercuList, BoviList, Uniprot and KEGG databases (See text for 
further details).
Additional file 2: Table S2. The list of identified proteins in bPPDs. 
Sequence coverage, number of unique peptides, as well as total weighted 
spectra as a semi-quantitative measure of protein abundance, are 
reported.
Additional file 3: Table S3. Dimethyl labeling-based quantification of 
proteins present in samples  It, NLand  Ip relative to sample S. Result of 
single replicates as well as average H:L and M:L ratios, their associated 
p-values and number of observations (unique peptides) are reported.
Additional file 4: Table S4. Proteins found differentially abundant in 
samples  It, NL and  Ip compared to sample S. The file contains three data 
sheets reporting 44, 34 and 30 proteins found at significantly different 
levels in samples It, NL and Ip, respectively. These proteins were mostly 
present at very low levels in all preparations. Fold changes >2 and <0.5 are 
reported in two separate lists.
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